Open AccessManagement of atypical chronic lymphocytic leukemia presenting with extreme leukocytosis
Author(s) -
Muddasani Ramya,
Talwar Neel,
SuarezLondono Jaime Andres,
Braunstein Marc
Publication year - 2020
Publication title -
clinical case reports
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.21
H-Index - 9
ISSN - 2050-0904
DOI - 10.1002/ccr3.2773
Subject(s) - ibrutinib , medicine , chronic lymphocytic leukemia , leukocytosis , oncology , bruton's tyrosine kinase , lymphoma , immunology , leukemia , pathology , cancer research , receptor , tyrosine kinase
Atypical chronic lymphocytic lymphoma (CLL) with CCND1 translocation is poorly described, particularly in the era of modern inhibitors of the B‐cell receptor pathway. We present a patient with atypical CLL who had a significant response to ibrutinib, highlighting the effectiveness of this agent in higher risk CLL subgroups.